AnHeart Therapeutics
Eric Kong has over 11 years of work experience in the field of chemistry analysis development. Eric spent 9 years at Novartis where they worked in the process R&D and production of APIs for GLP/IND/NDA/PPQ campaign projects. Eric also had 2 years of experience in the overall operation of a kilo-lab, overseeing safety, quality, and budget. In this role, they were responsible for all GLP campaign product production and global supply within the company. At STA Pharmaceutical, they worked as an Associate Director in CMC Project Management, where they managed and coordinated projects across multiple sites and departments. Their responsibilities included pre-formulation & solid state development, formulation process R&D, and GMP production & commercial production. Eric was also involved in new drug applications in China, the United States, and the European Union, supporting a total of 19 projects and completing 5 project submissions. Eric Kong is currently working as the CMC Director at AnHeart Therapeutics.
Eric Kong attended Shenyang Pharmaceutical University from 2005 to 2008, where they obtained a Bachelor's degree in Pharmaceutical Chemistry.
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.